TSFVIT04:	Subjects Meeting Specific On-treatment Hypotension Levels; Safety Analysis Set (Study jjcs - core)						
 	Active Study Agent 	Active Study Agent 	 	Risk Difference (%) (95% CI) 	Risk Difference (%) (95% CI) 	
 	Xanomeline High Dose 	Xanomeline Low Dose 	Placebo 	Xanomeline High Dose vs Placebo 	Xanomeline Low Dose vs Placebo 	
Blood Pressure (mmHg), n (%) 	N=53 	N=73 	N=59 	  	  	
N 	53 	71 	58 	 	 	
Systolic blood pressure<90 	0 	0 	4 (6.9%) 	-6.9 (-13.4, -0.4) 	-6.9 (-13.4, -0.4) 	
Diastolic blood pressure<60 	6 (11.3%) 	8 (11.3%) 	9 (15.5%) 	-4.2 (-16.8, 8.4) 	-4.2 (-16.1, 7.6) 	

Note: On-treatment is defined as blood pressure values obtained after the first dose and within [30 days] following treatment discontinuation. 	
Note: On-treatment is defined as blood pressure values obtained after the first dose and within [30 days] following treatment discontinuation.	
Note: On-treatment is defined as blood pressure values obtained after the first dose and within [30 days] following treatment discontinuation.	
Note: On-treatment is defined as blood pressure values obtained after the first dose and within [30 days] following treatment discontinuation.	
Note: On-treatment is defined as blood pressure values obtained after the first dose and within [30 days] following treatment discontinuation.	
Note: On-treatment is defined as blood pressure values obtained after the first dose and within [30 days] following treatment discontinuation.